XML 113 R30.htm IDEA: XBRL DOCUMENT v3.20.4
Acquisitions of businesses
 12 Months Ended
Dec. 31, 2020
Disclosure of acquisition of businesses [abstract]  
Acquisition of businesses
24. Acquisitions of businesses
Fair value of assets and liabilities arising from acquisitions of businesses
(USD millions)
2020
2019
2018
Property, plant and equipment
26
44
137
Right-of-use assets
32
Currently marketed products
196
3 550
2 531
Acquired research and development
8 600
342
10 224
Other intangible assets
218
22
1
Deferred tax assets
476
60
381
Non-current financial and other assets
49
8
19
Inventories
84
195
20
Trade receivables and financial and other current assets
109
4
90
Cash and cash equivalents
76
1 112
Deferred tax liabilities
– 1 977
– 107
– 2 874
Current and non-current financial debts
– 32
– 2
– 14
Current and non-current lease liabilities
– 44
Trade payables and other liabilities
– 144
– 178
– 627
Net identifiable assets acquired
7 669
3 938
11 000
Acquired cash and cash equivalents
– 76
– 1 112
Non-controlling interests
– 26
Goodwill
2 580
186
4 084
Net assets recognized as a result of acquisitions of businesses  1
10 173
4 124
13 946
 1  In 2018, net assets recognized as a result of acquisitions of businesses in the consolidated balance sheet from continuing operations were USD 13 660 million.
Note 2 details significant acquisitions of businesses, specifically, The Medicines Company and the Japanese business of AGI in 2020; Xiidra and IFM Tre, Inc. in 2019; and AAA, AveXis and Endocyte in 2018. The goodwill arising out of these acquisitions is attributable to the buyer specific synergies, the assembled workforce, and the accounting for deferred tax liabilities on the acquired assets. Goodwill of USD 74 million in 2020 (2019: USD 98 million, 2018: nil) is tax deductible.